Hand, Foot and Mouth Disease
Conditions
Brief summary
This study aims to evaluate the safety and immunogenicity of CJ-40010 after administration in healthy subjects
Detailed description
Enterovirus 71(EV71) and coxsackievirus A16(CVA16) are major causes of Hand-foot-and-mouth disease (HFMD) occurring in pediatric population. Although EV71 vaccine has been licensed in China, vaccine for CVA16-associated HFMD is currently not available anywhere. The purpose of this phase I study is to evaluate the safety and immunogenicity of EV71/CVA16 bivalent vaccine in healthy adults.
Interventions
BIOLOGICALCJ-40010 EV71 vaccine A dose
Inactivated vaccine against EV71, three doses, 28 days interval
BIOLOGICALCJ-40010 EV71 vaccine B dose
Inactivated vaccine against EV71, three doses, 28 days interval
BIOLOGICALCJ-40010 CVA16 vaccine C dose
Inactivated vaccine against CVA16, three doses, 28 days interval
BIOLOGICALCJ-40010 CVA16 vaccine D dose
Inactivated vaccine against CVA16, three doses, 28 days interval
BIOLOGICALCJ-40010 Bivalent vaccine E dose
Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
BIOLOGICALCJ-40010 Bivalent vaccine high dose
Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
BIOLOGICALPlacebo
Placebo, three doses, 28 days interval
Sponsors
HK inno.N Corporation
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
19 Years to 49 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy adult men and women aged ≥19 to \<50 years at the time of screening tests * Body mass index(BMI)\* of ≥18.0 kg/m2 to ≤27.0 kg/m2, with body weight of ≥55.0 kg to ≤90.0 kg for men and ≥50.0 kg to ≤90.0 kg for women at the time of screening tests \*BMI (kg/m2) = Body weight (kg) / {height (m)}2 * Determined by the investigator to be eligible for study participation based on the results of screening tests (medical examination by interview, physical examination, vital signs, ECG, and clinical laboratory tests) conducted within 4 weeks of the 1st IP administration * Intact deltoid muscle\* that allows administration of the investigational product \*Those who have a wound, scar, tattoo, skin disorder or infection on the expected investigational product administration site (deltoid muscle) that can affect safety evaluation cannot enter the study * Consent to use medically acceptable contraception\* throughout the study \*Medically acceptable contraception: Use of an intrauterine device with a demonstrated pregnancy failure rate, concurrent use of a barrier method (male or female) and spermicide, surgical contraception of the subject or partner (vasectomy, salpingectomy/tubal ligation, hysterectomy, bilateral oophorectomy) * Negative finding from a pregnancy test (urine hCG) at the time of the screening visit, after using medically acceptable contraception prior to 30 days of screening for women of childbearing potential\* \*Women of childbearing potential: Women who have not passed 1 year after menopause or not surgically sterilized (hysterectomy, bilateral oophorectomy) * Voluntary decision and provision of written consent on participation in this study
Exclusion criteria
* History of a hand-foot-mouth disease or history of a disease related with enterovirus(EV) infection such as herpangina, viral meningitis, encephalitis, acute hemorrhagic conjunctivitis or myocarditis within 3 months prior to the 1st IP administration * Medical history of an anaphylactic or similar acute reaction to CJ-40010 or similar vaccine * Febrile disease or infectious disease within 2 weeks prior to the 1st IP administration * Whole blood donation within 2 months or apheresis within 1 month prior to the 1st IP administration * Vaccination with other prevention vaccine within 2 months prior to the 1st IP administration * Use of an immunomodulator or immunosuppressant\* within 3 months prior to the 1st IP administration * e.g., Azathioprine, Cyclosporin, Interferon, G-CSF, Tacrolimus, Everolimus, Sirolimus * High dose corticosteroids (continuous use for 14 days or more at ≥20 mg/day for Prednisolone. However, use of inhaled, intranasal or topical corticosteroids is allowed irrespective of the administered dose). * History of a Guillain Barre syndrome * Excessive caffeine intake (\>5 units/day) or continuous alcohol consumption (\>21 units/week, 1 unit = 10 g of pure alcohol) or incapable of abstention from alcohol during the study * Participation in other clinical trial within 6 months prior to the 1st IP administration * Pregnant or breastfeeding women * Clinically significant hepatic, renal, neurological, respiratory, endocrine, hematology and oncology, cardiovascular, urological or psychiatric disease or such history * Positive serological finding (type B hepatitis test, type C hepatitis test, human immunodeficiency virus(HIV) test) * History of drug abuse or positive finding from a urine screening test for an abusive drug * Use or of any prescription medication or oriental medicine within 2 weeks or any over-the-counter(OTC) medication, health functional food or vitamin within 1 week prior to the 1st IP administration (however, those who administered an allowed drug as specified in the other exclusion criterion can enter the study) or expected use of such products * Administration of a blood product or blood-derived agent within 3 months prior to the 1st IP administration * Determined by the investigator to be ineligible for study participation due to other reason including clinical laboratory findings
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency and severity of adverse events of CJ-40010 (Safety of CJ-40010) | Week 0 to Week 32 | \- Frequency and severity of adverse events up to 32 weeks post first dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity of CJ-40010 : Anti-EV71 IgG titer | Week 0 to Week 32 | Serum EV71-specific IgG titers |
| Immunogenicity of CJ-40010 : Anti-CVA16 IgG titer | Week 0 to Week 32 | Serum CVA16-specific IgG titers |
| Immunogenicity of CJ-40010 : Geometric mean titer (GMT) of EV71 neutralizing antibody titers | Week 0 to Week 32 | Geometric mean titers based on neutralizing antibody titers. Measurement of fold-increase over baseline of neutralizing titers against EV71 |
| Immunogenicity of CJ-40010 : GMT of CVA16 neutralizing antibody titers | Week 0 to Week 32 | Geometric mean titers based on neutralizing antibody titers. Measurement of fold-increase over baseline of neutralizing titers against CVA16 |
Countries
South Korea
Contacts
Primary ContactSun Young Wang
Backup ContactJi Yeon Nam
Outcome results
None listed